WORKSHOP III MINIMAL RESIDUAL DISEASE MRD MONITORING IN ACUTE PROMYELOCYTIC LEUKEMIA:

Abstract

some issues related to its use as a means to predict clinical outcome but important issues remain to be clarified. In part this is related to the evolution and improvement in the treat-ment of APL. Four treatment-related developments have been particularly relevant to the state-of-the-art application of MRD in 2005. First, it was found by Fenaux, et al., that concurrent treatment with all-trans retinoic acid (ATRA) and chemotherapy (CT) resulted in superior long-term outcome compared to the sequential administration of these two forms of treatment.1 Second, Lo-Coco, et al., provided evi-dence that re-treatment at the time of molecular relapse dur-ing first remission provided improved clinical outcome com-pared to a historical control group not re-treated until the time of hematological relapse (HR).2 Third, Sanz, et al., defined pretreatment criteria to classify patients for risk o

Similar works

This paper was published in CiteSeerX.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.